Europe

After Brexit: new directions for clinical trials

If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

• The innovation paradox: why complex drug research is not being rewarded 12-07-2017
• Precision medicine: getting patenting spot on 12-07-2017
• GQ Life Sciences: searching for sequence IP 08-07-2017
• The quest for clarity continues 05-07-2017
• Advertising in Mexico: it pays to check your copy 30-06-2017

More europe features